Previous Article | Next Article ![]()
Infection and Immunity, August 2001, p. 5173-5176, Vol. 69, No. 8
Department of Medical and Molecular
Parasitology, New York University School of Medicine, New York, New
York 10010
Received 26 October 2000/Returned for modification 13 December
2000/Accepted 2 May 2001
An understanding of the antigen presentation mechanisms that
mediate induction of protective immune responses against malaria is
essential for the development of successful immunization approaches. Here we show that dendritic cells presenting Plasmodium
yoelii sporozoite antigens are able to activate specific
CD4+ and CD8+ T cells and initiate protective
immune responses against malaria in mice.
The intracellular parasite
Plasmodium is the causative agent of malaria, one of the
most prevalent human infectious diseases in the world, with high
mortality rates during childhood and complications in infected adults.
After injection by mosquito of Plasmodium sporozoites into
the vertebrate host, the sporozoites must infect hepatocytes before
developing into the pathogenic erythrocytic stages. Thus, protection
induced against malaria liver stages diminishes or abrogates further
development of the disease (15). In areas where malaria is
endemic, individuals generate partial protective immunity against
malaria only after several years of frequent exposure to the parasite.
However, complete protection against malaria can be induced by a few
inoculations of irradiated Plasmodium sporozoites (3,
16). Due to the lack of an in vitro system to generate large
amounts of sporozoites, broad use of an irradiated sporozoite-based
vaccine against malaria is not feasible. Therefore, an understanding of
the mechanisms that mediate induction of protective immune responses
against preerythrocytic forms of the parasite is important for the
development of alternative immunization approaches.
Activation of T cells by antigen-presenting cells (APCs) is required to
initiate specific immune responses. Dendritic cells (DCs) are a unique
type of APC because of their ability to induce primary immune responses
by efficient activation of naïve T cells (11). DCs
reside in tissues as immature cells with high phagocytic capacity.
Following activation and antigen capture, they migrate to the lymphoid
organs, where they prime antigen-specific CD4+ and
CD8+ T cells (1). Since the APCs that mediate
protective immune responses to malaria have not yet been identified, we
investigated the capacity of DCs to present Plasmodium
sporozoite antigens to T cells and induce inhibition of liver-stage
development of the parasite.
The ability of DCs to initiate protective antimalaria immune responses
was examined by adoptive transfer to naïve mice of DCs
presenting sporozoite-derived antigens. The activation of specific
CD4+ and CD8+ T cells and the degree of
protection against sporozoite infection were measured in these mice.
Primary cultures of immature DCs from BALB/c mice (haplotype
H-2Kd) were obtained by in vitro differentiation
of bone marrow-derived precursors during 10 days (29),
using the supernatant of the myeloma cell line Ag8653 expressing
mouse recombinant granulocyte-macrophage colony-stimulating factor as a
source of this cytokine (24). Analysis of the bone
marrow-derived cell population was performed using
fluorescence-activated cell sorting, which showed that these cells
expressed the distinctive DC surface marker CD11c, as well as major
histocompatibility complex (MHC) class I and II molecules. Activation
of these cells by the addition of lipopolysaccharide (LPS) (1 µg/ml)
for 24 h induced the characteristic DC increase of the
costimulatory molecules CD40, CD80, and CD86 and of MHC class I and II
molecules on the plasma membrane (29) (Fig.
1).
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.8.5173-5176.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Dendritic Cells Can Initiate Protective Immune
Responses against Malaria
![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References

View larger version (39K):
[in a new window]
FIG. 1.
Characterization of DC cultures by
fluorescence-activated cell sorting analysis. Control or LPS-activated
bone marrow-derived cell cultures were incubated with antibodies
against different DC markers. Thin lines, nonactivated DCs; thick
lines, LPS-activated DCs; shading, irrelevant IgG control staining.
FITC, fluorescein isothiocyanate.
Peptides containing the identified
H-2Kd-specific CD4+
(YNRNIVNRLLGDALNGKPEEK) (8) and
CD8+ (SYVPSAEQI) (20)
epitopes from the circumsporozoite protein (CS) of the rodent malaria
species P. yoelii were incubated for 1 h at a
concentration of 30 µg/ml with the mature DCs. The peptides comprising both epitopes are identical in P. yoelii
nonlethal (17X) and lethal (YM) strains. Peptides were allowed to bind
to the MHC molecules of DCs that were activated by incubation with LPS
(1 µg/ml) for 24 h. DCs were washed and transferred to
naïve BALB/c mice (7.5 × 105 DCs/mouse) by
intravenous injection. Twelve days after transfer of DCs, activation of
specific anti-CS CD4+ and CD8+ T cells was
detected using an ELISPOT assay for the production of gamma interferon
(IFN-
) (13, 19). For the ELISPOT assay, T cells were
enriched from spleen suspensions by the elimination of plastic adherent
and immunoglobin G (IgG)- and IgM-reactive cells. The numbers of
antigen-specific T cells are calculated by subtracting the mean spot
numbers in control wells without peptide (mean value of 273 spots per
106 cells) from the mean spot numbers in parallel cultures
where APCs (A20.2J cells) were preincubated with the corresponding
peptides. High numbers of specific CD4+ and
CD8+ T cells were found in mice injected with DCs pulsed
with the corresponding CS epitopes (Fig.
2A). Transfer of the same number of
control DCs did not induce a specific T-cell response. These results
indicate that DCs presenting sporozoite epitopes are able to initiate
specific antimalaria immune responses in naïve mice.
|
The degree of protection conferred by DCs presenting CS epitopes was
measured 2 weeks after adoptive transfer. Mice were challenged with
105 P. yoelii sporozoites (nonlethal parasite
line 17X) obtained by dissection of infected Anopheles
stephensi mosquito salivary glands. The degree of liver infection
was determined by competitive reverse transcription (RT)-PCR of
parasite 18S rRNA in mouse livers 42 h after sporozoite
inoculation (20). Mice immunized by adoptive transfer of
DCs loaded with the CS-derived CD8+ epitope displayed a
much lower level of parasite RNA in the liver than mice transferred
with DCs alone or DCs loaded with the CD4+ epitope (Fig.
2B). Although similar numbers of IFN-
-producing CD4+ and
CD8+ T cells were induced in the mice by DCs loaded with
the corresponding peptides (Fig. 2A), only activation of
CD8+ T cells inhibited development of parasites in the
liver (Fig. 2B).
In mouse models, protection induced by irradiated sporozoites is
mediated by CD8+ T cells to liver-stage parasites and is
dependent on IFN-
(21, 22, 28). To study whether
DC-induced protection is mediated by a similar mechanism, control DCs
or DCs loaded with the CS-derived CD8+ epitope were
transferred to groups of four IFN-
knockout mice [C129S7(B6)-IFNg;
Jackson] and the corresponding background control mouse strain. Ten
days later, protection against challenge with live sporozoites was
evaluated as described above. In contrast to normal mice, transfer of
DCs loaded with the CS-derived CD8+ epitope to IFN-
knockout mice did not inhibit the development of P. yoelii
parasites in the liver (Fig. 2C). These results indicate that, as
previously shown for immunization with irradiated sporozoites, the
protection induced by transfer of DCs is also mediated by IFN-
.
Increased replication of P. yoelii in the liver of IFN-
knockout mice was observed (Fig. 2C), confirming the inhibitory effect
of IFN-
on Plasmodium development in the liver
(12).
During the course of natural infections, correct processing of antigens
and loading of resulting peptides onto MHC molecules of APCs is
required to obtain T-cell activation. To test the ability of DCs to
process and present sporozoite CS protein epitopes, we infected DCs
with recombinant adenovirus expressing the CS protein of P. yoelii (AdPyCS) (18). DCs derived from BALB/c mice
were infected with AdPyCS (multiplicity of infection, 200) for 24 h before being transferred to naïve BALB/c mice (5 × 105 DCs/mouse). Transfer of infected DCs resulted in the
activation of specific anti-CS CD4+ and CD8+ T
cells (Fig. 3A) and in the inhibition of
development of parasites in the liver (Fig. 3B), as determined 2 weeks
later.
|
Transfer of the same number of AdPyCS-infected DCs derived from C57BL/6 mice (haplotype H-2Kb) into BALB/c mice (haplotype H-2Kd) did not result in activation of T cells (Fig. 3A) or protection against sporozoite challenge (Fig. 3B). Taken together these results indicate that the immune response generated in syngeneic mice is induced after specific processing and presentation of CS protein by DCs. The lack of activation of an immune response by allogenic DCs indicates that this response cannot be attributed to mouse infection with residual adenovirus particles or to uptake of CS antigens from the infected DCs by APCs of the recipient mice.
Protection against liver-stage malaria is mainly dependent on the induction of effective T-cell immune responses that eliminate infected hepatocytes (10, 21, 22). Therefore, the development of antimalaria vaccines against this stage is based on the activation of cytotoxic T-cell responses (6, 14, 23). Nonreplicating vaccines, such as inactivated pathogens, can elicit effective antibody responses; however, the induction of effector CD8+ T-cell responses has been difficult to achieve. Recombinant vaccines, including genetically modified viral vectors and DNA vaccines, can overcome this problem, as they can induce both effective antibody and CD8+-mediated responses in vivo (17, 25, 26). These responses can be enhanced by targeting expression of recombinant antigens to APCs, and in particular to DCs (2, 4, 5, 7, 9), or by coexpression of granulocyte-macrophage colony-stimulating factor (27, 30), a cytokine that enhances the maturation of DC precursors. These observations reveal the importance of DCs as mediators of protective immune responses that are triggered by these vaccines. Our results show that DCs can initiate CD8+-mediated immune responses against malaria liver stages and should be targeted to obtain effective antimalaria vaccines.
| |
ACKNOWLEDGMENTS |
|---|
We thank Ruth S. Nussenzweig and Moriya Tsuji for critically revising the manuscript; James M. Wilson for providing AdPyCS; and Ivette Caro and Sandy Nosseir for mosquito salivary gland dissection.
O.B.-R. was supported by the Starr Foundation. A.R. was supported by the American Liver Foundation.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Medical and Molecular Parasitology, New York University School of Medicine, 341 E. 25th St., New York, NY 10010. USA Phone: (212) 263-6589. Fax: (212) 263-8116. E-mail: rodria02{at}popmail.med.nyu.edu.
Editor: J. M. Mansfield
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. J. Liu, B. Pulendran, and K. Palucka. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:767-811[CrossRef][Medline]. |
| 2. | Chattergoon, M. A., J. J. Kim, J. S. Yang, T. M. Robinson, D. J. Lee, T. Dentchev, D. M. Wilson, V. Ayyavoo, and D. B. Weiner. 2000. Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered fas-mediated apoptosis. Nat. Biotechnol. 18:974-979[CrossRef][Medline]. |
| 3. | Clyde, D. F., H. Most, V. C. McCarthy, and J. P. Vanderberg. 1973. Immunization of man against sporozite-induced falciparum malaria. Am. J. Med. Sci. 266:169-177[CrossRef][Medline]. |
| 4. | Condon, C., S. C. Watkins, C. M. Celluzzi, K. Thompson, and L. D. Falo, Jr. 1996. DNA-based immunization by in vivo transfection of dendritic cells. Nat. Med. 2:1122-1128[CrossRef][Medline]. |
| 5. |
Deliyannis, G.,
J. S. Boyle,
J. L. Brady,
L. E. Brown, and A. M. Lew.
2000.
A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge.
Proc. Natl. Acad. Sci. USA
97:6676-6680 |
| 6. | Doolan, D. L., R. C. Hedstrom, M. J. Gardner, M. Sedegah, H. Wang, R. A. Gramzinski, M. Margalith, P. Hobart, and S. L. Hoffman. 1998. DNA vaccination as an approach to malaria control: current status and strategies. Curr. Top. Microbiol. Immunol. 226:37-56[Medline]. |
| 7. | Gentschev, I., G. Dietrich, S. Spreng, A. Kolb-Maurer, J. Daniels, J. Hess, S. H. Kaufmann, and W. Goebel. 2000. Delivery of protein antigens and DNA by virulence-attenuated strains of salmonella typhimurium and listeria monocytogenes. J. Biotechnol. 83:19-26[CrossRef][Medline]. |
| 8. | Grillot, D., M. Michel, I. Muller, C. Tougne, L. Renia, D. Mazier, G. Corradin, P. H. Lambert, J. A. Louis, and G. Del Guidice. 1990. Immune responses to defined epitopes of the circumsporozoite protein of the murine malaria parasite, Plasmodium yoelii. Eur. J. Immunol. 20:1215-1222[Medline]. |
| 9. |
Haicheur, N.,
E. Bismuth,
S. Bosset,
O. Adotevi,
G. Warnier,
V. Lacabanne,
A. Regnault,
C. Desaymard,
S. Amigorena,
P. Ricciardi-Castagnoli,
B. Goud,
W. H. Fridman,
L. Johannes, and E. Tartour.
2000.
The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens.
J. Immunol.
165:3301-3308 |
| 10. |
Hoffman, S. L.,
D. Isenbarger,
G. W. Long,
M. Sedegah,
A. Szarfman,
L. Waters,
M. R. Hollingdale,
P. H. van der Meide,
D. S. Finbloom, and W. R. Ballou.
1989.
Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes.
Science
244:1078-1081 |
| 11. | Mellman, I., S. J. Turley, and R. M. Steinman. 1998. Antigen processing for amateurs and professionals. Trends Cell Biol. 8:231-237[CrossRef][Medline]. |
| 12. | Mellouk, S., S. J. Green, C. A. Nacy, and S. L. Hoffman. 1991. IFN-gamma inhibits development of Plasmodium berghei exoerythrocytic stages in hepatocytes by an L-arginine-dependent effector mechanism. J. Immunol. 146:3971-3976[Abstract]. |
| 13. | Miyahira, Y., K. Murata, D. Rodriguez, J. R. Rodriguez, M. Esteban, M. M. Rodrigues, and F. Zavala. 1995. Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J. Immunol. Methods 181:45-54[CrossRef][Medline]. |
| 14. | Nardin, E., F. Zavala, V. Nussenzweig, and R. S. Nussenzweig. 1999. Pre-erythrocytic malaria vaccine: mechanisms of protective immunity and human vaccine trials. Parassitologia 41:397-402[Medline]. |
| 15. |
Nussenzweig, R. S., and C. A. Long.
1994.
Malaria vaccines: multiple targets.
Science
265:1381-1383 |
| 16. | Nussenzweig, R. S., J. Vanderberg, H. Most, and C. Orton. 1967. Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature 216:160-162[CrossRef][Medline]. |
| 17. | Ramshaw, I. A., and A. J. Ramsay. 2000. The prime-boost strategy: exciting prospects for improved vaccination. Immunol. Today 21:163-165[CrossRef][Medline]. |
| 18. | Rodrigues, E. G., F. Zavala, D. Eichinger, J. M. Wilson, and M. Tsuji. 1997. Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. J. Immunol. 158:1268-1274[Abstract]. |
| 19. | Rodrigues, M., S. Li, K. Murata, D. Rodriguez, J. R. Rodriguez, I. Bacik, J. R. Bennink, J. W. Yewdell, A. Garcia-Sastre, R. S. Nussenzweig, et al. 1994. Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity. J. Immunol. 153:4636-4648[Abstract]. |
| 20. |
Rodrigues, M. M.,
A. S. Cordey,
G. Arreaza,
G. Corradin,
P. Romero,
J. L. Maryanski,
R. S. Nussenzweig, and F. Zavala.
1991.
CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria.
Int. Immunol.
3:579-585 |
| 21. | Romero, P., J. L. Maryanski, G. Corradin, R. S. Nussenzweig, V. Nussenzweig, and F. Zavala. 1989. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 341:323-326[CrossRef][Medline]. |
| 22. | Schofield, L., J. Villaquiran, A. Ferreira, H. Schellekens, R. Nussenzweig, and V. Nussenzweig. 1987. Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 330:664-666[CrossRef][Medline]. |
| 23. | Seder, R. A., and A. V. Hill. 2000. Vaccines against intracellular infections requiring cellular immunity. Nature 406:793-798[CrossRef][Medline]. |
| 24. |
Stockinger, B.,
T. Zal,
A. Zal, and D. Gray.
1996.
B cells solicit their own help from T cells.
J. Exp. Med.
183:891-899 |
| 25. | Tang, D. C., M. DeVit, and S. A. Johnston. 1992. Genetic immunization is a simple method for eliciting an immune response. Nature 356:152-154[CrossRef][Medline]. |
| 26. |
Ulmer, J. B.,
J. J. Donnelly,
S. E. Parker,
G. H. Rhodes,
P. L. Felgner,
V. J. Dwarki,
S. H. Gromkowski,
R. R. Deck,
C. M. DeWitt,
A. Friedman, et al.
1993.
Heterologous protection against influenza by injection of DNA encoding a viral protein.
Science
259:1745-1749 |
| 27. |
Weiss, W. R.,
K. J. Ishii,
R. C. Hedstrom,
M. Sedegah,
M. Ichino,
K. Barnhart,
D. M. Klinman, and S. L. Hoffman.
1998.
A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine.
J. Immunol.
161:2325-2332 |
| 28. |
Weiss, W. R.,
M. Sedegah,
R. L. Beaudoin,
L. H. Miller, and M. F. Good.
1988.
CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites.
Proc. Natl. Acad. Sci. USA
85:573-576 |
| 29. |
Winzler, C.,
P. Rovere,
M. Rescigno,
F. Granucci,
G. Penna,
L. Adorini,
V. S. Zimmermann,
J. Davoust, and P. Ricciardi-Castagnoli.
1997.
Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures.
J. Exp. Med.
185:317-328 |
| 30. | Xiang, Z., and H. C. Ertl. 1995. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 2:129-135[CrossRef][Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|